Skip to content

PFAS Restrictions: What Should You Be Doing?

September 29, 2021
1:00 PM ET

Per- and polyfluoroalkyl substances (PFAS) continue to receive regulatory focus both in the U.S. and around the world. Dubbed “forever chemicals” due to their persistence and bio-accumulative properties, these man-made chemicals are the subject of ever-increasing regulatory restrictions and requirements on the international, national, state, and even local levels.

With even more regulations looming on the horizon, many companies face the crucial question, “What should we be doing?”

Join in the conversation to receive answers to this question and gain insight on recent developments related to PFAS.

View Recorded Presentation

Related

Event

Webinar- Dark Patterns in Healthcare: Navigating Patient Consent, Website Privacy, and Emerging Regulatory Risk 

Healthcare organizations increasingly rely on digital tools to engage patients, streamline intake, and improve care coordination. At the same time, regulators are closely scrutinizing whether online interfaces, consent mechanisms, and patient-facing technologies improperly influence or manipulate patient choices through so-called “dark patterns.”

Explore more
Legal Updates

Texas’ Hemp THC Crackdown is Now in Effect: What Businesses Need to Know

As of Jul. 31st, Texas is enforcing tough new restrictions on hemp-derived THC products, and it’s changing the game for manufacturers, distributors, and retailers across the state. This isn’t one new law; it’s the Texas Department of State Health Services’ (DSHS) messy revival of dormant 2021 rules after a Texas Supreme Court ruling, on top of separate consumable-hemp regulations that kicked in earlier this year and are still being fought over in court. Bottom line: the rules have shifted more than once in 2026, and businesses need a clear picture of what’s banned, what’s still fine, and what’s still up in the air.

Explore more
Legal Updates

Nasdaq's $5 Million MVLS Rule Approved: What Issuers Need to Know About the Final Rule and the SEC’s Temporary Stay of Effectiveness

The SEC has approved Nasdaq’s new $5 million Market Value of Listed Securities (MVLS) continued listing standard, while temporarily staying its effectiveness pending potential Commission review. Although the final rule retains Nasdaq’s accelerated delisting framework, it expands the Nasdaq Hearings Panel’s authority to grant limited relief, giving certain issuers additional time to demonstrate compliance with Nasdaq’s more stringent initial listing standards.

Explore more